



OCT and HVF Makes Glaucoma Easy: Cases that Beg to Differ

David Fleischman, MD, MS, FACS
 Perioperative Medical Director, UNC Hillsborough
 Associate Professor
 Director, Glaucoma Fellowship
 Director, Ocular Trauma
 University of North Carolina at Chapel Hill




Disclosures

- Optopol, Inc (PI)



Define... Glaucoma

- What is glaucoma?
 - » An IOP-dependent eye disease that may result in vision loss
- Typical features:
 - » Regional atrophy
 - » Corresponding visual field changes



Pattern Recognition

- Superior and Inferior Thinning
- Typical Visual Field Loss

UNCGeye

Pattern Recognition

UNCGeye

Pattern Recognition


- Intraocular pressures
 - » Are they on glaucoma meds already?
- Corneal thickness
 - » Ensure no corneal edema
- Older age
- Race (depending on form of glaucoma)
- Family history


UNCGeye


Case 1

Case 1

[illegible]








Case 4

- 73-year-old White female
- Family history: brother, nephew
- Denies trauma, steroid use
- TMax: 15 mm Hg both eyes
- CCT: 561 μ m and 547 μ m
- Gonioscopy: CBB 360 both eyes
- Color Plates: 11 out of 11 both eyes




Case 4 Synopsis


- Primary open angle glaucoma
 - Note typical advancement of visual field defects over time
 - Be skeptical of very fast visual field changes, especially at low-normal pressures


Case 5


- 72-year-old White female
- Family history: unknown (adopted)
- Denies trauma, steroid use
- TMax: OD: 15 mm Hg OS: 16 mm Hg
- CCT: 522 μ m and 521 μ m
- Gonioscopy: CBB 360 both eyes
- Color Plates: 6 out of 6 Ishihara bilaterally



Case 5





 THE YANLUK CENTER		Samuel F. Yanluk, DC, FACPC
Shelli Rubin	6252914	
Height/weight figure 8's - exactly on the base	2 minutes at a time 3x per day	
Stretch your shoulders/upper back with pulleys	2 reps 3x per day	
10th Monday with Tummy - 10x	2 reps 3x per day	
Cardio-machine, position side	10 minutes 3x per day	
Stretching suggests to increase urinary per centage of calcium available crystals in urine	10 minutes 3x per day	
Dr. EPOCH's Exercises / Improved Function		
10. Elbow Flexion	2.5x	
11. Cat/Mag. Concentration	2.5x	
Problem-Specific Supplements	Follows out how much problems you're advised to take less	
A. Glutamine	2 per day 1st and 2nd last time (see much = advised)	
M. Curcumin	2.5x per 2 days when you feel better longer	
A. Thymine	1 per day	
1. Vitamin C	1 per day	
2. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
3. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
4. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
5. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
6. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
7. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
8. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
9. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
10. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
11. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
12. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
13. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
14. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
15. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
16. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
17. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
18. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
19. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
20. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
21. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
22. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
23. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
24. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
25. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
26. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
27. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
28. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
29. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
30. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
31. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
32. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
33. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
34. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
35. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
36. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
37. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
38. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
39. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
40. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
41. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
42. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
43. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
44. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
45. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
46. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
47. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
48. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
49. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
50. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
51. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
52. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
53. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
54. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
55. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
56. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
57. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
58. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
59. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
60. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
61. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
62. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
63. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
64. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
65. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
66. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
67. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
68. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
69. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
70. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
71. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
72. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
73. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
74. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
75. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
76. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
77. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
78. P. Mena	2 per day 1st and 2nd last time (see much = advised)	
79. A. Thymine	2 per day 1st and 2nd last time (see much = advised)	
80. P. Mena	2 per	

[illegible]

Case 5

Cytotoxic Effects of Curcumin in Human Retinal Pigment Epithelial Cells

Margrit Hollborn^{1*}, Rui Chen¹, Peter Wiedemann¹, Andreas Reichenbach², Andreas Bringmann¹,
 Alexander J. W. J. van der Vliet³

Leon Kohen^{1,3}

Abstract

Background: Curcumin from turmeric is an ingredient in curry powders. Due to its antiinflammatory, antioxidant and anticarcinogenic effects, curcumin is a promising drug for the treatment of cancer and retinal diseases. We investigated whether curcumin alters the viability and physiological properties of human retinal pigment epithelial (RPE) cells *in vitro*.

Methodology/Principal Findings: Cellular proliferation was investigated with a bromodeoxyuridine immunoassay, and chemotaxis was investigated with a Boyden chamber assay. Cell viability was determined by trypan blue exclusion. Apoptosis and necrosis were analyzed by DNA fragmentation (ELISA), GADAP experiments, and caspase-3 determined by real-time PCR, and secretion of VEGF and bFGF was examined using ELISA. The phosphorylation level of proteins was revealed by Western blotting. The proliferation of IPE cells was slightly increased by curcumin at 10 μ M and strongly reduced by curcumin above 50 μ M. Curcumin at 50 μ M increased slightly the chemotaxis of the cells. Curcumin reduced the expression of VEGF and bFGF and induced apoptosis and altered the permeability of the monolayer. Curcumin at 50 μ M increased the expression of p38 MAPK, whereas low concentrations of curcumin stimulated the expression of bFGF and HGF, high concentrations caused downregulation of both factors. Curcumin decreased dose-dependently the viability of IPE cells via induction of early necrosis above 10 μ M and delayed apoptosis (above 1 μ M). The cytotoxic effect of curcumin involved activation of caspase-3, increased membrane permeability, oxidative stress, increased phosphorylation of p38 MAPK and decreased phosphorylation of Akt protein.

Conclusion: It is concluded that curcumin at concentrations described to be effective in the treatment of tumor cells and in inhibiting death of retinal neurons ($\sim 10 \mu\text{M}$) has adverse effects on RPE cells. It is suggested that, during the intake of curcumin as concomitant therapy of cancer or in the treatment of eye diseases, retinal function should be monitored carefully.

Citation: Hultborn M, Chen R, Wiedemann P, Reichenbach A, Bringmann A, et al. (2015) Cytotoxic Effects of Curcumin in Human Retinal Pigment Epithelial Cells. *PLoS ONE* 10(2): e0096033. doi:10.1371/journal.pone.0096033

Received: August 10, 2012; **Accepted:** February 18, 2013; **Published:** March 26, 2013

Copyright: © 2013 Hellöien et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from the Deutsche Forschungsgemeinschaft (BO 1340/7-1) and the Goethever Erster Stiftung (Dannover, Germany). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: hollnath.medizin@uni-leipzig.de






Figure 4. Concentration-dependent effects of curcumin (A) and triamcinolone acetonide (B) on the viability of RPE cells. The percentage of viable cells was evaluated 24 h after addition of the test substances to the culture medium. Data are means \pm SEM of 5–7 independent experiments carried out in triplicate using cells from different donors, and are expressed in percent of untreated control (100%). Significant difference vs. control: * $p < 0.05$; ** $p < 0.01$.


Case 6

- 77-year-old White female
- Family history: mother
- Denies trauma, steroid use
- TMax: OD: 33 mm Hg and OS: 22 mm Hg
- CCT: 558 μm and 556 μm
- Gonioscopy: open prior to CE/IOL
- Status post trabeculectomy in 2011
- Notable: pigment dispersion syndrome, +/- low tension glaucoma equivalent





Case 6






Case 6








Case 6 Synopsis

- **Pigmentary Glaucoma**
 - » Highly elevated intraocular pressures can result in necrotic cell death with glialization of the nerve
 - » Tends to burn out with time (affecting visual field and OCT progression)
 - » However, can develop low-tension glaucoma equivalent state



Case 7

- 76-year-old Black male
- Family history: maternal aunt, maternal cousin
- Denies trauma, steroid use
- TMax: 17 mm Hg both eyes
- CCT: 523 μm ; 527 μm
- Gonioscopy: SS 360
- History of pituitary macroadenoma: s/p resection in 2009, 2nd resection in 2012; radiotherapy in 2012 (51.24 Gy)





Case 7

- On exam:
 - The patient's visual acuity was 20/400 OD and 20/200 OS on initial eval
 - Current eval: OD: counting fingers and OS: counting fingers

Case 7

- Visual Fields:
 



Case 7

Visual Fields:

OS

OD

OS

OD

OS

OD

OS

OD

UNGe

Case 7

MRI (2017) Impression:
"similar size and appearance
of residual enhancing
suprasellar mass with optic
chiasm compression."

Neurosurg Eval: "Stable
mass, not growing. Unlikely to
be causing recent changes in
vision."

A

B

C

UNGe

Case 7

ONH and RNFL OU Analysis: Optic Disc Cube 200x200 OD OS

RNFL Thickness Map

RNFL Deviation Map

Neuroretinal Rim Thickness

RNFL Thickness

RNFL Deviation Map

RNFL Thickness

RNFL Thickness Map

RNFL Deviation Map

Neuroretinal Rim Thickness

RNFL Thickness

RNFL Deviation Map

RNFL Thickness

UNGe


14

Case 7

OD - 7/18/2022			
Visual Acuity	20/40	Visual Evoked	1.0
Visual Field	Normal	Visual Evoked	1.0
Visual Evoked	1.0	Visual Evoked	1.0
Visual Evoked	1.0	Visual Evoked	1.0
Visual Evoked	1.0	Visual Evoked	1.0


OS - 7/18/2022			
Visual Acuity	20/20	Visual Evoked	1.0
Visual Field	Normal	Visual Evoked	1.0
Visual Evoked	1.0	Visual Evoked	1.0
Visual Evoked	1.0	Visual Evoked	1.0
Visual Evoked	1.0	Visual Evoked	1.0

Follow up visit: OD: 20/400 and OS: 20/200




Case 7 Synopsis


- Compression is compression, even if stable
 - » Trabs don't treat tumors
 - » Again, be skeptical of progression at very low intraocular pressures





Case 8

- 54-year-old Black male
- Family history: negative
- Denies trauma, steroid use
- TMax: 23 mm Hg right eye, 46 mm Hg left eye
- CCT: 555 μ m ; 548 μ m
- Gonioscopy: ciliary body 360, both eyes
- Notable: proliferative diabetic retinopathy; no evidence of NVI/NVA/PAS; has had vitrectomy for non-clearing vitreous hemorrhage (left eye)









Case 9

- 30-year-old White female
- Family history: father, paternal grandmother
- Denies trauma, steroid use
- TMax: 18 mm Hg and 19 mm Hg on Betimol (unknown Tmax without meds)
- CCT: 532 μm : 522 μm
- Gonioscopy: CBB 360 both eyes
- Color Plates: 10/11 both eyes
- Notable: Congenital nystagmus

Case 9


Case 9


Supplemental Case 9


- 62 year-old White female
- Family history: negative
- Denies trauma, steroid use
- TMax: 18 mm Hg and 19 mm Hg
- CCT: 578 μm and 565 μm
- Gonioscopy: open to SS 360 prior to CE/IOL





Case 9+

















Case 10 Synopsis

- Susac Syndrome:
 - Rare syndrome which includes encephalopathy, branch retinal artery occlusions, and inner ear disease
- Branch retinal artery occlusion or branch retinal vein occlusions can look like arcuate scotomas

UNICEYE

Case 11 Synopsis

- Retinitis pigmentosa: diffuse progressive dysfunction of rod photoreceptors, then cone photoreceptors and RPE
- Migration of retinal pigment into the anterior chamber has been suggested as a cause of RP-associated glaucoma (open angle mechanisms)
- However, RP may be associated with ACG in rare instances
 - » Visual fields and OCT are difficult to interpret in these cases



Features Suggesting Non-Glaucomatous Diagnosis

History	Young age
	Rapid onset
	Rapid progression
	Headache (other than typical migraine)
	Other neurologic symptoms
Exam	Loss of visual acuity or visual field out of proportion to cupping
	Severe dyschromatopsia
	Afferent pupillary defect without significant asymmetry of cupping
	Ocular motility or other neurologic defects
Visual field	Atypical visual field: temporal > nasal, respect of vertical meridian, inferior altitudinal defect, central scotoma
Optic disk	Pallor of preserved rim



Moster M, Kay M. Glaucoma: The Neuro-ophthalmic differential Diagnosis. J Curr Glaucoma Pract Jan-Apr 2008;2(1):33-38.

Features Suggesting Non-Glaucomatous Diagnosis

Differentiation of Compressive from Glaucomatous Optic Neuropathy with Spectral-Domain Optical Coherence Tomography

Conclusions: Compressive optic neuropathy is associated with significantly thinner nasal and temporal sectors compared with OAG, whereas OAG results in larger cups and cup volume with OCT measurements. The Heidelberg retinal tomograph is not able to differentiate CON from normal discs. *Ophthalmology* 2014;121:1516-1523 © 2014 by the American Academy of Ophthalmology.

Design: Cross-sectional, observational study.
Participants: A total of 120 eyes from 123 patients with CON (89 eyes) or OAG (58 eyes) and controls (73 eyes).
Methods: Univariate and multivariate analyses of HRT parameters, SD-OCT circumferential retinal nerve fiber layer (RNFL) thickness, and optic nerve head (ONH) parameters.
Main Outcome Measures: Circumpapillary RNFL, OCT ONH parameters, and HRT parameters.
Results: The univariate analysis of OCT parameters demonstrated significant differences between the temporal and nasal quadrants: clock hours 3 (55 vs. 73 μm), 4, 8 (93.9 vs. 70.7 μm), 9, and 10; vertical cup-to-disc ratio (C/D) (0.6 vs. 0.8) and cup volume (0.2 vs. 0.5) ($P < 0.001$) between patients with CON and OAG, respectively. The CON discs were significantly different from normal discs for all OCT parameters except cup volume. The CON discs were not significantly different from normal discs for HRT parameters, except for mean RNFL thickness and cup shape measure. The OAG discs were significantly different from normal discs in all HRT and OCT parameters ($P < 0.001$). Multivariate analysis demonstrated that the OCT 3 o'clock temporal sector, average C/D ratio, vertical C/D ratio, and cup volume measurements were able to differentiate OAG from CON.
Conclusions: Compressive optic neuropathy is associated with significantly thinner nasal and temporal sectors compared with OAG, whereas OAG results in larger cups and cup volume with OCT measurements. The Heidelberg retinal tomograph is not able to differentiate CON from normal discs. *Ophthalmology* 2014;121:1516-1523 © 2014 by the American Academy of Ophthalmology.



Features Suggesting Non-Glaucomatous Diagnosis

The Cupped Disc

Who Needs Neuroimaging?

David S. Greenfield, MD,¹ R. Michael Siatkowski, MD,¹ Joel S. Glaser, MD,^{1,2} Norman J. Scharz, MD,^{1,2} Richard K. Parish II, MD²

Conclusions: Anterior visual pathway compression is an uncommon finding in the neuroradiologic evaluation of patients with a presumptive diagnosis of normal-tension glaucoma. Younger age, lower levels of visual acuity, vertically aligned visual field defects, and neuroretinal rim pallor may increase the likelihood of identifying an intracranial mass lesion. *Ophthalmology* 1998;105:1866-1874

Intervention: The medical records of consecutive glaucoma patients with normal intraocular pressure who underwent brain magnetic resonance imaging or computed tomography scanning as part of a diagnostic evaluation between January 1, 1985, and July 1, 1995, were reviewed. A masked reading of optic nerve photographs and visual fields was performed by one observer. A similar analysis was performed on a control group of consecutive patients with nonglaucomatous optic nerve cupping with known intracranial mass lesions.

Main Outcome Measures: The neuroradiologic findings, clinical characteristics, optic nerve head appearance, and patterns of visual field loss were compared between groups.

Results: None of the patients diagnosed with glaucoma had neuroradiologic evidence of a mass lesion involving the anterior visual pathway. Compared to control subjects, patients with glaucoma were older ($P = 0.0001$), had better visual acuity ($P = 0.002$), greater vertical loss of neuroretinal rim tissue ($P = 0.0001$), more frequent optic disc hemorrhages ($P = 0.01$), less neuroretinal rim pallor ($P = 0.0001$), and more nerve fiber bundle visual field defects aligned at the horizontal midline ($P = 0.0001$). Visual acuity less than 20/40, vertically aligned visual field defects, optic nerve pallor in excess of cupping, and age younger than 50 years were 77%, 81%, 90%, and 93% specific for nonglaucomatous cupping associated with compressive lesions, respectively.

Conclusions: Anterior visual pathway compression is an uncommon finding in the neuroradiologic evaluation of patients with a presumptive diagnosis of normal-tension glaucoma. Younger age, lower levels of visual acuity, vertically aligned visual field defects, and neuroretinal rim pallor may increase the likelihood of identifying an intracranial mass lesion. *Ophthalmology* 1998;105:1866-1874

Conclusions

- OCT RNFL and visual fields are powerful tools in diagnosing and managing glaucoma
- Pattern recognition of OCT – vertical thinning with corresponding visual field defects that respect the raphe – is a key skill to learn
- But: Be aware of conditions that can complicate the interpretation of these tests

UNG eye
